Preliminary report: cyclosporin in treatment of severe active ulcerative colitis

doi:10.1016/0140-6736(90)91521-B

The Lancet

Volume 336, Issue 8706, 7 July 1990, Pages 16-19

https://doi.org/10.1016/0140-6736(90)91521-B Get rights and content

Abstract

Intravenous cyclosporin (4 mg/kg daily) was given to fifteen patients with severe active ulcerative colitis, fourteen of whom had failed to respond to at least 10 days' treatment with intravenous steroids. In the acute phase of the open trial, eleven patients (73%) improved and avoided colectomy; the mean response time was 5·8 days. Patients who responded were maintained on oral cyclosporin (6-8 mg/kg daily) for a 6-month chronic phase. Six of the eleven patients have been weaned from steroids and remain in clinical and endoscopic remission 5-18 months after discontinuation of cyclosporin; three are well at 5 months and their steroid dose is being tapered; one patient relapsed after 5 months on oral cyclosporin and underwent colectomy; and one patient failed to show continued improvement with oral cyclosporin but is in clinical remission after changing to mercaptopurine treatment. Slight self-limiting adverse side-effects of cyclosporin were seen, but none necessitated withdrawal from the study. Cyclosporin seems to be an effective treatment for patients with severe active ulcerative colitis who have not responded to steroids.

References (31)

Sc Truelove et al.
Intensive intravenous regimen for severe attacks of ulcerative colitis
Lancet
(1974)
Rj Dickinson et al.
Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis
Gastroenterology
(1980)
K. Masuda et al.
Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease
Lancet
(1989)
S. Gupta et al.
Cyclosporin in ulcerative colitis
Lancet
(1984)
Te Starzl et al.
Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy
Lancet
(1984)
Dp Jewell et al.
Immunology of inflammatory bowel disease
Scand J Gastroenterol
(1985)
G. Jamerot et al.
Intensive intravenous treatment for ulcerative colitis
Gastroenterology
(1985)
S. Meyers et al.
Corticotrophin versus hydrocortisone in the intravenous treatment of ulcerative colitis
Gastroenterology
(1983)
Rs Savidge
Trimethoprim and sulfamethoxazole in ulcerative colitis
Postgrad Med J
(1969)
G. Nussenblatt et al.
Treatment of intraocular inflammatory disease with cyclosporin A
Lancet
(1983)

Jf Borel et al.

Cyclosporine A as a new approach to therapy of autoimmune disease

Ann NY Acad Sci

(1986)

Mc Allison et al.

Cyclosporine A for Crohn's disease

Aliment Pharmacol Ther

(1987)

J. Brynskoff et al.

A placebo controlled double blind randomized trial of cyclosporine therapy in active chronic Crohn's disease

N Engl J Med

(1989)

Sc Truelove et al.

Cortisone and corticotrophin in ulcerative colitis

Br Med J

(1959)

Ap Kirk et al.

Controlled trial of azathioprine in chronic ulcerative colitis

Br Med J

(1982)

Cited by (310)

Web-based and machine learning approaches for identification of patient-reported outcomes in inflammatory bowel disease
2022, Digestive and Liver Disease
Messages from an Internet forum are raw material that emerges in a natural setting (i.e., non-induced by a research situation).
The FLARE-IBD project aimed at using an innovative approach consisting of collecting messages posted by patients in an Internet forum and conducting a machine-learning study (data analysis/language processing) for developing a patient-reported outcome measuring flare in inflammatory bowel disease meeting international requirements.
We used web-based and machine learning approaches, in the following steps. 1) Web-scraping to collect all available posts in an Internet forum (23 656 messages) and extracting metadata from the forum. 2) Twenty patients were randomly assigned 50 extracted messages; participants indicated whether the message corresponded or not to the flare phenomenon (labeling). If yes, participants were asked to identify excerpts from the text they considered significant flare markers (annotation). 3) The set of annotated messages underwent a vocabulary analysis.
The phenomenon of flare was circumscribed with the identification of 20 surrogate flare markers classified into five dimensions with their frequency within extracted labeled data: impact on life, symptoms, extra-intestinal manifestations, drugs and environmental factors. Web-based and machine-learning approaches met international recommendations to inform the content and structure for the development of patient-reported outcomes.
Female reproductive health and inflammatory bowel disease: A practice-based review
2022, Digestive and Liver Disease
Inflammatory bowel diseases, namely ulcerative colitis and Crohn's disease, occur worldwide and affect people of all ages, with a high impact on their quality of life. Sex differences in incidence and prevalence have been reported, and there are also gender-specific issues that physicians should recognize. For women, there are multiple, important concerns regarding issues of body image and sexuality, menstruation, contraception, fertility, pregnancy, breastfeeding and menopause. This practice-based review focuses on the main themes that run through the life of women with inflammatory bowel diseases from puberty to menopause. Gastroenterologists who specialize in inflammatory bowel diseases and other physicians who see female patients with inflammatory bowel diseases should provide support for these problems and offer adequate therapy to ensure that their patients achieve the same overall well-being and health as do women without inflammatory bowel diseases.
The importance of sarcopenia as a prognostic predictor of the clinical course in acute severe ulcerative colitis patients
2021, Digestive and Liver Disease
Citation Excerpt :
Baseline characteristics, perioperative data, and laboratory data were collected from the IBD database. Baseline characteristics included age, BMI, sex, colonoscopy, CT images, patient health-related quality of life (HRQoL), Mayo score (including stool frequency, rectal bleeding, and physician assessment of disease activity) [12], the Lichtiger score (including a clinical index of 8 factors) [10,13], and the ulcerative colitis endoscopic index of severity (UCEIS). Perioperative data included type of surgery, operation time, and postoperative complications.
Acute severe ulcerative colitis (ASUC) is a life-threatening condition that requires timely referral for therapy. Sarcopenia has been associated with clinical outcomes of inflammatory bowel disease (IBD). This study investigated the role of sarcopenia in predicting the clinical course of ASUC.
This retrospective cohort study included ASUC patients with abdominal CT scans. Univariate and multivariable regression analyses were performed to identify a practical predictive index for the clinical course of ASUC.
Of 233 included patients, 151 had intravenous corticosteroid (IVS) failure, among whom 32 received surgery without medical rescue therapy. Fifty patients underwent colectomy after medical rescue therapy failure. Of these 82 surgical patients, 42 suffered postoperative complications. Multivariable regression analysis showed that sarcopenia remained an independent risk factor for IVS failure (OR=2.969; 95% CI, 1.547–5.701; p = 0.001), colectomy after medical rescue therapy failure (OR=3.411; 95% CI, 1.147–10.141; p = 0.027), and postoperative complications after colectomy (OR=4.157; 95% CI, 1.364–12.667; p = 0.012). During follow-up, patients with colectomy after first-line treatment had a lower comprehensive complication index and better health-related quality of life.
Sarcopenia is useful in predicting the clinical course and postoperative outcomes of ASUC.
Assessing Severity of Disease in Patients with Ulcerative Colitis
2020, Gastroenterology Clinics of North America
British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis
2020, The Lancet Gastroenterology and Hepatology
Immune checkpoint inhibitors are a novel class of cancer treatment that have improved outcomes for a subset of cancer patients. They work by antagonising inhibitory immune pathways, thereby augmenting immune-mediated antitumour responses. However, immune activation is not cancer-specific and often results in the activation of immune cells in non-cancer tissues, resulting in off-target immune-mediated injury and organ dysfunction. Diarrhoea and gastrointestinal tract inflammation are common and sometimes serious side-effects of this type of therapy. Prompt recognition of gastrointestinal toxicity and, in many cases, rapid institution of anti-inflammatory or biologic therapy (or both) is required to reverse these complications. Management of organ-specific complications benefits from multidisciplinary input, including engagement with gastroenterologists for optimal management of immune checkpoint inhibitor-induced enterocolitis. In this British Society of Gastroenterology endorsed guidance document, we have developed a consensus framework for the investigation and management of immune checkpoint inhibitor-induced enterocolitis.
Exploring the role of oxidative stress and the effect of N-acetylcysteine in thiopurine-induced liver injury in inflammatory bowel disease: A randomized crossover pilot study
2024, Basic and Clinical Pharmacology and Toxicology

View all citing articles on Scopus

View full text

Preliminary report: cyclosporin in treatment of severe active ulcerative colitis

Abstract

Lancet

Gastroenterology

Lancet

Lancet

Lancet

Immunology of inflammatory bowel disease

Scand J Gastroenterol

Intensive intravenous treatment for ulcerative colitis

Gastroenterology

Corticotrophin versus hydrocortisone in the intravenous treatment of ulcerative colitis

Gastroenterology

Trimethoprim and sulfamethoxazole in ulcerative colitis

Postgrad Med J

Treatment of intraocular inflammatory disease with cyclosporin A

Lancet

Cyclosporine A as a new approach to therapy of autoimmune disease

Ann NY Acad Sci

Cyclosporine A for Crohn's disease

Aliment Pharmacol Ther

A placebo controlled double blind randomized trial of cyclosporine therapy in active chronic Crohn's disease

N Engl J Med

Cortisone and corticotrophin in ulcerative colitis

Br Med J

Controlled trial of azathioprine in chronic ulcerative colitis

Br Med J